The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a (8) SGB V for medicinal products for the active substance roflumilast (ATC code according to WHO: R03DX07) within the framework of a so-called "open house model". All interested and suitable pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V, subject to the specification of uniform conditions and a uniform access procedure. There is no exclusivity. The purchase quantity is unknown when the agreement is concluded and is particularly dependent on the demand of the insured, the development of the number of insured, the prescription behavior of the contract doctors and the dispensing and stockpiling behavior of the public pharmacies. The client does not guarantee minimum purchase quantities.
For further information see point II.2.4) of the announcement.
The agreement can be concluded at any time and on the same terms. Individual contract negotiations are not carried out.
Interested pharmaceutical companies can request the participation documents (discount agreement, self-declaration for the absence of reasons for exclusion, declaration of conformity) via the e-mail address given under I.1). Agreements within the framework of this model are concluded in the period from August 18, 2020 to September 30, 2020. Interested parties must submit the fully completed and signed participation documents (self-declaration for non-existence of reasons for exclusion, discount agreement in duplicate, declaration of conformity) for the first time by August 17, 2020, then by the 15th of a month, by post to the office named under I.1) . It depends on the access of both AOK PLUS. If the 15th of a month falls on a Saturday, Sunday or national holiday, the next working day will take the place of such a day. If received later (after August 17, 2020 or the 15th of a month), the submitted participation documents will be taken into account on the 15th of the following month.
The discount agreement comes into force as soon as AOK PLUS has signed the discount agreement after receipt of the complete and signed documents by the pharmaceutical company. The signing takes place until the end of the month in which the participation documents must have been received by AOK PLUS. Organizationally, AOK PLUS requires a preliminary run of around half a month to register the discount agreement. The initial labeling of discount medicinal products in the pharmacy software takes place from the second month following the receipt period for the participation documents. This time can vary if the deadlines for reporting dates on the nationwide AOK contract reporting portal DatRabatt are changed or re-established. A discount agreement is concluded with all pharmaceutical companies that meet the participation requirements and confirm this by signing the requested documents.
The contract ends on 30.9.2022 at the latest, regardless of the date of conclusion of the contract. AOK PLUS reserves the right to prematurely end the open house process, especially if exclusive discount agreements have been concluded. In this case, the contracts already concluded end in accordance with the contractual provisions. According to the experience of AOK PLUS, exclusive discount agreements generally come into force eight to twelve months after the publication of the relevant announcement in the supplement to the Official Journal of the European Union. The future contractors in the open house model are asked to inform themselves regularly in this regard in the supplement to the Official Journal of the European Union.